Aleukemic Leukemia Cutis: Case Report and Review of Literature

Abstract

Aleukemic leukemia cutis (LC) is an extremely rare clinical presentation. All patients eventually develop acute leukemia, mostly monocytic and myelomonocytic types. It is a diagnostic challenge, resolved by careful immunophenotyping and cytochemistry. The diagnosis indicates a poor prognosis. Here, we report a case of an 85-year-old white male with LC, who had normal peripheral blood and bone marrow histology. The fragility of our patient precluded any definite anti-leukemic therapy.

Keywords: Acute myeloid leukemia, cytochemistry, histology in leukemia, immunophenotyping, leukemia cutis

Introduction

As leukemia cutis (LC) is a somewhat rare condition and has been reported in many leukemic subtypes, the exact incidence is not well characterized. Of the acute myelogenous leukemia developing in patients with human T-lymphotropic virus type 1 (HTLV-1), one of the highest incidences of LC is noted. Acute myelomonocytic leukemia (AML-4) and AML-M5 have the highest rate of cutaneous infiltration of all the FAB subtypes and has been recorded as high as 30-50%.[2-5]

In most cases of LC, the patients have a preceding or concurrent diagnosis of systemic disease. In as many as 7% of patients, LC precedes bone marrow or blood involvement.[6] The prevalence of 2.9%–3.7% of AML cases have been noted to present with LC. This excluded patients with HTLV-induced AML which is much higher in Japan and Caribbean.[7] In general, LC patients have a poor survival. Here, we present a rare case of aleukemic LC (ALC) in an elderly male with negative bone marrow and blood involvement, which posed a diagnostic challenge initially.

Case Report

An 85-year-old man with past medical history of Alzheimer’s early dementia, localized prostate cancer treated with X-ray telescope presented with widespread erythematous rash and cutaneous nodules in February 2017. The rash first appeared around patient’s neck and then involved his trunk and lower extremities over a period of 3 weeks. The patient reported generalized weakness since onset of skin lesions. He denied fever, chills, chest pain, shortness of breath, weight loss, changes in bowel or bladder habits. The patient denied a history of recent travel or change in medications. He was a lifetime nonsmoker, reported minimal alcohol intake. Punch biopsy of one of the abdominal wall lesions was performed. Meanwhile, there was a rapid progression of skin lesions leading to hospitalization. Physical examination was significant for multiple nontender, erythematous, and violaceous lesions and nodules of various sizes involving the neck, upper chest, back, and thighs up to knees bilaterally. Complete blood count revealed mild normocytic anemia with hemoglobin of 12.5 g/dl, normal white blood cell and platelet counts. Peripheral blood smear revealed slight increase in the percentage of monocytes in peripheral blood (20.1%) without absolute monocytosis. Chemistry profile revealed minimal transaminitis, mild alkaline phosphatase elevation; normal serum and urine electrophoresis except minimal hypergammaglobulinemia, normal serum lactate dehydrogenase, and kidney function testing. Serum lysozyme level was elevated at 21.1 mg/ml (normal 5–11). Flow cytometry on skin biopsy was noncontributory because of paucity of cells. Skin biopsy sections revealed diffuse atypical cellular infiltrate in the upper dermis. The epidermis was uninvolved.

Address for correspondence:
Dhauna Karam, Bharat Agrawal
Department of Hemato-Oncology, Captain James A. Lovell Federal Health Care Centre, Chicago, Illinois, USA

Access this article online
Website: www.ijmpo.org
DOI: 10.4103/ijmpo.ijmpo_75_17
Quick Response Code:

How to cite this article: Karam D, Agrawal B. Aleukemic leukemia cutis: Case report and review of literature. Indian J Med Paediatr Oncol 2018;39:443-5.
The infiltrate consisted of large cells with large blastic nuclei with folds or a reniform appearance. The cells were positive for CD4, CD43, CD68, and lysozyme. There was weak staining for bcl-6 in many cells, but this did not account for true positivity. There was no significant positivity in the cells of interest for CD2, CD3, CD5, CD7, CD8, CD20, CD79a, PAX6, CD30, ALK-1, CD10, CD163, myeloperoxidase, CD34, CD15, CD56, CD123, CD117, and EBER. The findings were consistent with LC that appeared to show monocytic differentiation. Bone marrow aspiration and biopsy revealed the presence of all hematopoietic cell lines with normal progressive maturation [Figures 1 and 2]. Promonocytes and mature monocytes were slightly increased. Blasts and promonocytes accounted for only 3.6% or 500 cell count [Figure 3]. Core biopsy showed areas of hypercellularity, normal CD34 count with no increase in blasts. Flow cytometry revealed a minor population of monoclonal normal sized B lymphocytes. There was no evidence of an expanded population of leukocytic blasts or plasma cells. Fragility of our patient precluded any anti-neoplastic therapy.

Discussion

LC is the invasion of neoplastic leukocytes or their early forms into the different layers of skin or subcutis.[8] The lesions may take different appearances and are highly variable in the presentation. They may look like flesh colored to violaceous papules, nodules, or plaques.[9] Terms such as granulocytic sarcoma, monocytic sarcoma, primary extra medullar leukemia, and chloroma have been used as synonyms for LC. Terms such as myeloid or lymphoid cutis have been used to further characterize the type of leukemia cells.[10]

LC usually presents as a manifestation of previously diagnosed acute or chronic leukemias, lymphoid malignancies, myelodysplastic syndromes, or blastic phase of chronic myeloid leukemia. In rare cases, LC may precede the development of systemic disease, then known as ALC. A dermatologist, not uncommonly is involved in aiding the diagnosis. In the latter, a drastic change in chemotherapy regimen will be needed.[11]

LC is often associated with many other sites of extensive involvement, and generally a very poor prognosis has been noted.[12-15] The pathophysiology and mechanism leading to migration of leukemic cells to the skin is not well understood. It has been proposed that chemokine integrin and other adhesion cell adhesion molecule 1 molecules may promote homing of T and B leukemic cells. Acute leukemia patients with t (8:21) translocation, expression of CD 56 have been linked to extramedullary disease.[14]

In HTLV-1-induced leukemia cases, the rich expression of CCR4, chemokine receptor on the leukemia cell surface could be involved in the tendency of adult T-cell leukemia to involve the skin. In the skin, the ligands thymus activation regulated chemokine (TARO/CCL 17) and macrophage involved chemokine (MDC/CCL 22) are present.[17]

The factors connected with cutaneous infiltration include aneuploidy of chromosomes, acute myeloid leukemia with
monocytic differentiation and involvement of other extra medullary sites. In acute monocytic leukemia, there is an expression of T cell-related antigens on the cell surface. This may induce homing to skin selectively.[18,19]

In a study of 18 cases of acute myelomonocytic LC, 14 patients demonstrated cutaneous lymphocytes antigen (CLA) staining. The presence of CLA may provide a predilection of migration to skin in those leukemic cells. A study by Kaddu et al. revealed an average survival term in AML to 7.5 months.[20] Our patient has ALC with monocytic differentiation in the skin. Considering his advanced age and developing dementia, the patient and his family were reluctant to initiate therapy.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**